IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

Core Viewpoint - IceCure Medical Ltd. will announce its financial and operational results for the year ended December 31, 2025, on March 17, 2026, before the Nasdaq Stock Market opens, followed by a conference call to discuss these results and other corporate developments [1]. Company Overview - IceCure Medical specializes in developing and marketing advanced liquid-nitrogen-based cryoablation therapy systems aimed at destroying both benign and cancerous tumors through freezing [1]. - The company's primary focus areas include breast, kidney, bone, and lung cancer, providing a minimally invasive alternative to surgical tumor removal [1]. - The flagship product, ProSense®, is marketed globally and has received necessary clearances and approvals in regions including the United States, Europe, and Asia [1]. Upcoming Events - A press release detailing the financial results will be issued before the market opens on March 17, 2026, with a conference call scheduled for 11:00 a.m. EDT on the same day [1]. - The conference call can be accessed via a live webcast, and a recording will be available afterward [1].